S100 Proteins: Novel Oxidant Scavengers In Allergic Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$505,814.00
Summary
Allergic inflammation includes conditions such as dermatitis and asthma. Asthma, affects one in 10 adults and one in 6 Australians, costing ~$720 million/annum. We will characterize new mediators of oxidant defence which have suppressive effects on key pathogenic processes. The novel oxidative changes in S100 proteins may lead to new diagnostic reagents and new strategies for therapy. Results will open new frontiers in asthma biology and will apply to other chronic inflammatory diseases.
Methylation-sensitive T Cell Genes And Childhood Food Allergy.
Funder
National Health and Medical Research Council
Funding Amount
$461,232.00
Summary
Australia has the highest reported prevalence food allergy in the world. Despite this, little is known about how allergy develops. Mounting evidence implicates environmentally induced disruption of the genetic blueprint via a process known as epigenetics. We are combining the strengths of food challenge proven food allergy with assessment of immune functioning & cutting edge genomics, to extensively characterise the pathways leading to food allergy in children.
Towards Reducing The Susceptibility Of “high Risk” Infants To Allergic Asthma By Therapeutic Modulation Of Immunoregulatory Functions In The Pregnant Mother.
Funder
National Health and Medical Research Council
Funding Amount
$445,681.00
Summary
This project will deliver information in relation to the potential use and underlying modes of action of a therapeutic agent fed to pregnant mothers at high risk for atopic children, to protect against allergic asthma development in their offspring. Furthermore, the project will address the benefits of this therapeutic agent in relation to protection against inflammation induced preterm birth.
Maternal Diet Rich In Eggs And Peanuts To Reduce Food Allergies: A Randomised Controlled Trial.
Funder
National Health and Medical Research Council
Funding Amount
$3,719,516.00
Summary
Food allergies now affect more than 1 in every 10 children. Recently, babies have been found to be at risk of developing a food allergy even before they start eating solid foods. We have discovered that baby immune responses can be improved by mothers eating more eggs during the first weeks of breastfeeding. Thus we are undertaking this research trial to determine whether mothers regularly eating more eggs and peanuts during pregnancy and breastfeeding will reduce food allergies in their babies.
Probiotic Prawn Oral Immunotherapy (ProPIT) For Treatment Of Prawn Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,865,369.00
Summary
A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.
A New Target For Allergic Inflammation: The Sphingolipid Pathway
Funder
National Health and Medical Research Council
Funding Amount
$588,617.00
Summary
Collectively, allergic diseases contribute immensely to the burden of health care in Australia. Notably, allergic reactions are symptomatic responses to a normally innocuous environmental antigen. Allergic diseases include asthma, hay fever, food allergy, anaphylaxis, insect sting and drug allergy. This project aims to understand the underlying mechanisms associated with allergic reactions such that it may aid in the identification of novel targets for the development of new treatments.
Regulatory Roles Of Mast Cells In Cutaneous Dermatitis In Vivo
Funder
National Health and Medical Research Council
Funding Amount
$586,965.00
Summary
Allergic conditions that can affect the skin, such as contact dermatitis or eczema are common amongst Australians. Although not life threatening, these common skin conditions can cause considerable physical diability and be expensive to treat. The major focus of our research is to define how dermal mast cells can be modulated to help limit the tissue changes and damage associated with these skin conditions, and ultimately develop improved treatments in the future.
The Regulation Of IgE Antibody Production By Antigen-specific B Cells
Funder
National Health and Medical Research Council
Funding Amount
$454,105.00
Summary
Asthma and other allergies are caused by the inappropriate production of IgE antibodies by the immune system. IgE is not produced in response to most infections but the controls that normally prevent IgE production are unknown. We have identified two separate molecules that prevent IgE production during immune responses. In this proposal we aim to investigate how these controls work. This information may help to devise strategies for controlling IgE production and therefore allergic disease.
Phase I/IIa Trials Of A Novel T-cell Epitope-based Peptide Therapy For Peanut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,440,000.00
Summary
Peanut allergy affects ~2% of the population and is the major cause of food triggered deaths from anaphylaxis. Typically peanut allergy is lifelong. Currently there is no specific treatment. Our vast experience in immunology for house dust mite and grass immunotherapy allowed us to identify critical components of peanut proteins needed as a safe vaccine to build tolerance to peanut foods. Now we will progress this novel and revolutionary vaccine through early phase clinical trials.
Tissue Specific T Cells Mediate Drug Hypersensitivity
Funder
National Health and Medical Research Council
Funding Amount
$1,253,980.00
Summary
T cells are immune cells that create dangerous and fatal drug allergies affecting the skin. An individual’s genetic makeup only partially explains predisposition to these reactions, we believe the missing link is contained in immune signatures specific to the skin. We aim to identify drug-specific T cells in the skin and develop a sensitive test to screen for rare, dangerous T cells in the blood. This will enable prediction and prevention of severe drug allergy and development of safer drugs.